Grey Wolf Therapeutics is thrilled to announce a landmark funding achievement, successfully raising $50 million to advance its pioneering work in immuno-oncology and autoimmune diseases. Founded by an esteemed collective of scientists, drug developers, and investors, Grey Wolf is dedicated to exploring the vast therapeutic potential of ERAP-driven antigen modulation. As a clinical-stage drug discovery and development company operating in the UK and Australia, Grey Wolf is revolutionizing the way immunologically-driven diseases are treated through its innovative technology focused on inhibiting endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2). This unique approach targets the antigen presentation pathway by transforming tumor cells, making them more recognizable to the immune system for effective destruction. Unlike traditional therapies that merely stimulate the immune response, Grey Wolf’s strategy directly enhances tumor visibility by modulating the neoantigen repertoire, thereby widening the impact of immunotherapy. This recent funding will help accelerate the development of clinical candidates against this validated target, enabling us to work hand in hand with prestigious academic and commercial partners in drug discovery. The Grey Wolf team comprises experts with profound knowledge in immuno-oncology, antigen presentation, and drug development, all of whom are passionate about delivering next-generation therapies for patients who desperately need new treatment options. This investment marks a significant step forward for our mission to redefine therapeutic possibilities in the fight against cancer and autoimmunity. For further details about our innovative approach and ongoing projects, visit our website or contact us at enquiries@gwt.bio.
Catalyzing a Paradigm Shift: Grey Wolf Therapeutics Secures $50M in Series B Funding for Innovative Immunotherapy Solutions
Recently funded · $50.0M Series bPharmaceuticals
Get the full Grey Wolf Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
